# A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

> **NCT02187861** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 163 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02187861
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-01
- **Primary completion:** 2016-09-27
- **Final completion:** 2018-03-16
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2019-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187861, "A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02187861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*